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Abstract
Background:  The aims of this study were to describe outcome with respect to persistent
psychotic symptoms, relapse of positive symptoms, hospital admissions, and application of
treatment by coercion among patients with recent onset schizophrenia being adherent and non-
adherent to anti-psychotic medication.
Materials and methods: The study included 50 patients with recent onset schizophrenia,
schizoaffective or schizophreniform disorders. The patients were clinically stable at study entry and
had less than 2 years duration of psychotic symptoms. Good adherence to antipsychotic medication
was defined as less than one month without medication. Outcomes for poor and good adherence
were compared over a 24-month follow-up period.
Results: The Odds Ratio (OR) of having a psychotic relapse was 10.27 and the OR of being
admitted to hospital was 4.00 among non-adherent patients. Use of depot-antipsychotics were
associated with relapses (OR = 6.44).
Conclusion: Non-adherence was associated with relapse, hospital admission and having persistent
psychotic symptoms. Interventions to increase adherence are needed.
Trial registration: Current Controlled Trials NCT00184509. Key words: Adherence,
schizophrenia, antipsychotic medication, admittances, relapse.
Background
Antipsychotic medications have reduced the number of
recurrent psychotic episodes among persons with schizo-
phrenia [1]. Poor adherence to antipsychotic medication
in schizophrenia have been associated with rehospitalisa-
tion [2,3] and relapse [4] in cross sectional studies and
studies monitoring hospital admissions among patients
being in shortage of supplies of antipsychotic medications
[5]. Data from the recent Clinical Antipsychotic Trials of
Intervention of Effectiveness (CATIE) study revealed that
74 % of the patients discontinued their medication before
18 months, i.e. either to non-adherence or to another
antipsychotic medication [6]. There is, however, a paucity
of prospective studies that in detail compare the develop-
ment of symptoms and disability among medication
adherent and non-adherent patients with recent onset
schizophrenia. Robinson [7] demonstrated a high fre-
quency of rehospitalisations in a group of patients with
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schizophrenia containing both non-adherent patients
and patients with a planned discontinuation of antipsy-
chotic medication. Non – adherent patients might have
different clinical characterisations than patients with
planned discontinuation of their medication due to a
long time without alarming symptoms.
The present report is a part of a randomized controlled
trial of two years continued integrated treatment com-
pared with standard treatment in recent-onset schizophre-
nia [8,9] [see Additional file 1, 2, 3]. The two
interventions seemed to be equal in effects on adherence
to medication and the proportions of patients that were
adherent to medication throughout the study were much
the same in the integrated treatment and the standard
treatment groups. The aims of the present report were to
compare outcome with respect to persistent psychotic
symptoms, relapse of positive symptoms, hospital admis-
sions and application of treatment by coercion among
patients with recent onset schizophrenia being adherent
and non-adherent to anti-psychotic medication.
Materials and Methods
Sample
Consecutive patients referred to a specialized psychiatric
team for psychosis were asked to participate in the study.
The catchment area of the team was the northeast half of
Sør-Trøndelag County in the middle of Norway during
the first 2 years of the study and the entire county for the
rest of the inclusion period. The whole county has a pop-
ulation of about 270.000 inhabitants. The recent-onset
patients were selected for the study if they were diagnosed
with DSM-IV [10] schizophrenia, schizoaffective or schiz-
ophreniform disorders by psychologists or psychiatrists
trained to administer the Structured Clinical Interview for
the DSM-IV [11] reliably. Clinically stable patients aged
between 18 and 35 years who were prescribed antipsy-
chotic medication and expected to reside in the county for
at least 1 year after inclusion were asked to participate in
the study. Patients with major substance use disorders or
mental retardation were excluded. Recent-onset was
defined as the emergence of distinct initial psychotic
symptoms for the first time within the past 2 years. Very
brief and transient experiences of psychotic symptoms
prior to the past 2 years were not classified as distinct psy-
chotic symptoms. Efforts were made to get referrals of all
patients with a recent onset psychotic disorder in the
catchment area. Invitations for study referral were sent to
the psychiatric inpatient units, outpatient clinics, and gen-
eral practitioners in the catchment area. Written informed
consent was obtained after the procedures were fully
explained to the patients and baseline assessments com-
pleted before inclusion from all included patients. The
study was approved by The Regional Committee for
Research Ethics, Middle Norway.
Interventions
All the 50 included patients received standard treatment
which was regular case management with antipsychotic
drugs, supportive housing and day care, crisis inpatient
treatment at 1 of 2 psychiatric hospitals, rehabilitation
that promoted independent living and work activity, brief
psychoeducation, and supportive psychotherapy. In addi-
tion, the patients randomized to integrated treatment
received structured family psychoeducation, cognitive –
behavioural family communication and problem solving
skills training, intensive crisis management provided at
home, and individual cognitive-behavioural strategies for
residual symptoms and disability [12,13]. More details of
the intervention and the results on new episodes, rehospi-
talisation, function and adherence to antipsychotic medi-
cation are reported elsewhere [8,9]. The two interventions
seemed to be equal in effects on adherence to medication.
The dose of antipsychotic medication was kept to the low-
est effective level. Although combination therapy and
switch of antipsychotics occurred, monotherapy was pre-
ferred and plasma assays were used on clinical indications
to optimise dose and to verify adherence. The physicians
had no restrictions when they selected antipsychotics.
Some of the patients having problems adhering to oral
medication were offered depot injections.
Assessments
Registration of antipsychotic medication adherence was
based on patient interviews. Information on adherence
was also gathered from therapists, carers, plasma assays,
and patient records. The information on adherence gath-
ered from plasma assays was not assessed on a regular
basis. If a patient later revealed that she or he had given
incorrect information about adherence at an earlier visit,
the records for adherence were corrected. Medication
adherence was recorded at inclusion and bimonthly for
the 2 years, and information gathered at later visits and
information from informal carers, therapists and patient
records was used to compensate for missing values.
Adherence was graded on a 4 point scale according to Tar-
rier [14]: 0: Up to 1 week without medication, 1: Up to 1
month without medication or 4 times more than 1 week
without medication, 2: Up to 5 months without medica-
tion, 3: five months or more without medication. Patients
with 1 month or more or 4 single weeks or more without
medication were rated as non-adherent with medication.
Patients receiving depot injections of antipsychotics at any
time were recorded as depot users. Because use of depot
antipsychotics was nearly always associated with non-
adherence with oral antipsychotics, adherence with oral
antipsychotics was also compared with non-adherent
patients and the depot users combined. Target Psychotic
Symptoms measured each individual's unique hallucina-
tions, delusions and thought disorders on a 0–7 scale
[15]. Suggesting symptom exacebarations, extra measureBMC Psychiatry 2008, 8:32 http://www.biomedcentral.com/1471-244X/8/32
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times were executed. Brief Psychiatric Rating Scale, BPRS,
was assessed bi-monthly [16]. The Positive and Negative
Symptom factors derived for first episode schizophrenia
were used to measure these dimensions [17].
Global Assessment of Functioning; GAF [10], assessed
overall functioning at 0, 12 and 24 months.
Continuous records were kept of medication and psycho-
social treatment adherence, hospital admissions and sui-
cidal behaviour.
Ratings were made by independent raters who were blind
to treatment conditions and trained to obtain a 0.8 kappa
coefficient of inter-rater reliability on all rating scales.
Operationalised variables
Psychotic recurrences and exacerbations: An episode of
relapse was defined as a two-point increase and a score of
six or seven on the Target Symptoms Ratings Scale (0–7)
AND a score of six or seven on one of the key psychotic
symptom items on the BPRS (1–7). In addition this was
confirmed by an independent person (researcher, family
member, clinician, case manager, etc) as a significant
worsening [18]. Persistent psychotic symptoms were
defined as scoring more than four on BPRS hallucinations
or unusual thought content for more than six consecutive
months during the study period. Symptoms at baseline
were assessed by the Brief Psychiatric Rating Scale (BPRS),
Target Symptoms Rating Scale and Global Assessment of
Function (GAF). Substance abuse was not systematically
assessed after the patients were included in the study.
Records were kept of medication and psychosocial treat-
ment adherence, hospital admissions and suicidal behav-
iour. All included patients were included in the outcome
analyses.
Statistics
Categorical factors were compared using Chi Square tests.
Ordinal variables were compared using the Mann-Whit-
ney test. To predict outcome, i.e. persistent psychosis,
relapse and admittances to hospital, separate logistic
regression analyses were performed with adherence to
antipsychotic medication or use of depot antipsychotics
as the explanation variable. All data analyses were per-
formed with the Statistical Package for Social Sciences Ver-
sion 14.0. An alfa level of 0.05 was selected.
Results
Of 168 consecutive referrals, 96 patients met the criteria
for schizophrenic disorders. Forty six patients were
excluded; 21 were not recent onset, 4 had substance
abuse, 4 lived outside of the catchment area, 4 would not
give written consent, 2 had mental retardation and 11 did
not recover from the initial psychotic episode. One of the
included patients moved to another region and 6 patients
received limited psychosocial treatment and follow-up.
However, it was possible to reach all patients for evalua-
tions. Demographic and clinical characteristics at baseline
are shown in Table 1. The 19 women and 31 men who
were included in the study came from hospital wards (57
%), outpatient clinics (23 %) and general practitioners
(21 %). Patients were clinically stable at baseline and were
assumed to be adherent with medication. At the end of
the study, 5 (10 %) patients revealed that they did not take
their medication as prescribed at baseline. All the patients
had been prescribed antipsychotic medication. During the
2 years, 37/50 patients were given first generation antipsy-
chotics, 12/50 patients were given second generation
antipsychotics excluding clozapine and 16/50 were given
clozapine.
Good adherence was found in 19 of 29 patients that any-
time during the trial received oral first generation antipsy-
chotics, 10 of 12 patients that anytime during the trial
received second generation antipsychotics and 12 of 16
patients receiving clozapine (ChiSqu = 1.44 df = 2, p =
0.5). Among patients with only one medication during
the whole trial, good adherence was found in 11 of 17
receiving oral first generation antipsychotics, 3 of 4 receiv-
ing second generation antipsychotics and 5 of 7 receiving
clozapine (ChiSqu = 0.21 df = 2, p = 0.9). Patients with
good adherence with oral or depot antipsychotic medica-
tion combined were more seldom persistent psychotic,
had fewer relapses and admittances to hospital, fewer days
in hospital and fewer days in-or outpatient admittance by
coercion than patients non-adherent to antipsychotics
(Table 2). Ten of 20 patients admitted to hospital were
non-adherent to oral and depot antipsychotic medication
combined while 6 of 30 patients not admitted to hospital
were non-adherent to oral and depot antipsychotic medi-
cation combined. Eleven of 17 patients with a major
Table 1: Baseline characteristics of the 50 included patients.
Age in years (SD) 25.4 (4.6)
Female 19
Male 31
Hospitalised before study 42
Diagnosis
Schizophrenia 40
Schizoaffective 6
Schizophreniform 4
Mean BPRS score (SD) 40 (7.6)
Mean GAF score (S.D.) 50 (10.6)
Contact with family No (%)
Living with parents/family 28 (56)
In weekly contact with parents/family 14 (28)
None or little contact 8 (16)
Days hospitalised last 12 months before study, mean 
(SD)
124 (105)BMC Psychiatry 2008, 8:32 http://www.biomedcentral.com/1471-244X/8/32
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recurrence were non-adherent while 5 of 33 patients with-
out a major recurrence were non-adherent to oral or depot
antipsychotic medication combined (Table 2). Patients
with good adherence to oral antipsychotics compared to
non-adherent patients and users of depot antipsychotics
combined were more seldom persistent psychotic, had
fewer relapses, a higher GAF at 2 years and better improve-
ment in GAF during the 2 years (Table 2). Users of depot
antipsychotics had more major relapses, higher number
of hospitalisations, more days admitted by coercion as in-
and outpatients and a lesser improvement in GAF through
the 2 years compared to patients that not used depot
antipsychotics (Table 2). Among the 22 patients that were
non-adherent to oral antipsychotics, 4 of the 6 women
and 7 of the 16 men were admitted to hospital during the
2 years. The non-adherent women had more days outpa-
tient treatment by coercion (p = 0.010, Mann-Whitney
test) and more days inpatient treatment by coercion (p =
0.049, Mann-Whitney test) than the non-adherent men
(Table 3).
Among the 12 patients receiving depot antipsychotics, 8
were treated with depot when included in the study. Of
these 8, 2 used depot the whole period with good adher-
ence, 2 had good adherence to depot, changed to oral
antipsychotics with bad adherence and 4 had good adher-
ence to depot, changed to oral with good adherence. Four
patients used oral antipsychotics when included, had bad
adherence and changed to depot antipsychotics with good
adherence.
This means that among the 12 patients treated with depot
antipsychotics some time during the study, 6 were adher-
ent throughout the 2 years, while 6 were non-adherent.
Five of 6 depot users in the non-adherent group had a
relapse compared to 3 of 6 in the adherent group. One of
Table 3: Sex differences in adherence to antipsychotic medication, use of depot antipsychotics, psychotic symptoms, relapse and 
admittances to hospital through two years in recent onset schizophrenia
Adherence with oral or depot antipsychotics Adherence with oral antipsychotics Use of depot antipsychotics
Good Not good Chi Squ P Good Not good Chi Squ P Not use Use P
Men N = 31 N = 18 N = 13 N = 15 N = 16 N = 24 N = 7
Persistent psychotic 2 (11%) 7 (54%) 6,69 ,010 1 (7%) 8 (50%) 7,06 ,008 5 (21%) 4 (57%) ,15 F
Relapse 3 (17%) 8 (62%) 6,64 ,010 2 (13%) 9 (56%) 6,23 ,013 7 (29%) 4 (57%) ,21 F
Admitted to hospital 4 (22%) 7 (54%) 3,30 ,069 4 (27%) 7 (44%) 0,99 ,320 7 (29%) 4 (57%) ,21 F
Women N = 19 N = 16 N = 3 N = 13 N = 6 N = 14 N = 5
Persistent psychotic 4 (25%) 0 (0%) 1,0 F 3 (23%) 1 (17%) 1,0 F 3 (21%) 1 (20%) 1,0 F
Relapse 3 (19%) 3 (100%) ,021 F 1 (8%) 5 (83%) ,003 F 2 (14%) 4 (80%) ,017 F
Admitted to hospital 6 (38%) 3 (100%) ,087 F 5 (38%) 4 (67%) ,350 F 6 (43%) 3 (60 %) ,628 F
F = Fischers exact test
Table 2: Adherence to antipsychotic medication, use of depot antipsychotics, psychotic symptoms, relapse and admittances to hospital 
through two years in recent onset schizophrenia.
Adherence with oral or depot antipsychotics Adherence with oral antipsychotics Use of depot antipsychotics
Good 
N = 34
Not good 
N = 16
Chi Squ P Good 
N = 28
Not good 
N = 22
Chi Squ P Not use 
N = 38
Use 
N = 12
Chi Squ P
Persistent psychotic 6 (18%) 7 (44%) 3.85 .050 4 (14%) 9 (41%) 4.54 .033 8 (21%) 5 (42%) 2.01 .156
Relapse 6 (18%) 11 (69%) 12.66 .000 3 (11%) 14 (64%) 15.38 .000 9 (24%) 8 (67%) 7.51 .006
Admitted to hospital 10 (29%) 10 (63%) 4.96 .026 9 (32%) 11 (50%) 1.64 .201 13 (34%) 7 (58%) 2.21 .137
Median (Range) Median (Range) P Median (Range) Median (Range) P Median (Range) Median (Range) P
Days in hospital 0 (0–295) 12 (0–264) .038 0 (0–295) 1 (0–264) .242 0 (0–295) 12 (0–264) .133
Nb of hospitalisations 0 (0–7) 1 (0–16) .011 0 (0–4) 1 (0–16) .074 0 (0–4) 1 (0–16) .048
Days inpatient 
coercion
0 (0–235) 0 (0–332) .004 0 (0–235) 0 (0–332) .013 0 (0–332) 10 (0–262) .008
Days outpatient 
coercion
0 (0–514) 0 (0–365) .049 0 (0–17) 0 (0–514) .006 0 (0–360) 0 (0–514) .004
GAF two years 59 (15–91) 48 (32–85) .116 64 (34–91) 48 (15–85) .014 61 (32–91) 50 (15–65) .065
GAF change 7 (-19–16) 2 (-24–18) .154 9 (-15–45) 0 (-20–33) .008 8 (-20–45) 0 (-18–15) .040BMC Psychiatry 2008, 8:32 http://www.biomedcentral.com/1471-244X/8/32
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6 depot users in the adherent group and all 6 depot users
in the non-adherent group were hospitalised (p = 0.015,
Fischer Exact test) (Table 4).
Discussion
Consequences of non adherence to antipsychotic 
medication
Non-adherence with oral or depot antipsychotic medica-
tion combined were associated with increased frequencies
of relapses, being persistent psychotic and an increased
risk of being admitted to hospital in this group of patients
with recent onset schizophrenia. This is in accordance
with earlier reports of patients being in shortage of antip-
sychotic medication being frequently admitted to hospital
[19].
Also measured in total number of days in hospital, in
number of admittances, number of days inpatient and
outpatient treatment by coercion, the patients non-adher-
ent to oral or depot antipsychotic medication had less
favourable outcomes than the adherent group. Register
based studies describe much the same tendency [5,19].
The relapse rate after discontinuation of antipsychotic
medication is believed to be more than 50% [20,21] and
more than 50% of patients readmitted to hospital have
discontinued their medication [22,23]. Even in the
present study where the authors assume 90 % of the
patients were adherent to medication at inclusion, 50 %
of the patients admitted to hospital during 2 years were
non – adherent to antipsychotic medication. Non-adher-
ence to antipsychotic medication was associated with an
Odds Ratio of 10.27 of having a major psychotic relapse.
Robinson [7] demonstrated a high frequency of rehospi-
talisations in a group of patients with schizophrenia con-
taining both non-adherent patients and patients with a
planned discontinuation of antipsychotic medication.
The patients that planned, together with their physician,
to discontinuate their antipsychotic medication might
have a much more benign illness than non-adherent
patients included in the same discontinuation group.
Days admitted by coercion as inpatients and as outpa-
tients were more frequent among non-adherent patients
in the present study. There is a hope that improved adher-
ence to antipsychotic medication might make patients
with schizophrenia more likely to be treated without coer-
cion. Patients with good adherence to oral antipsychotics
had a higher GAF level at 2 years and some improvement
in GAF level during the 2 years compared to non-adherent
patients including the depot users. This better outcome
among patients adherent to oral antipsychotic medication
might be interpreted as a result of the continuous availa-
bility of medication, but there is also the possibility that it
is easier for patients with a good function and low level of
symptoms to take their medication on a daily basis. The
association between poor outcome, increased symptoms,
low function and non-adherence is by most authors
believed to be a causative relationship; i.e. nonadherence
is leading to poor outcome. There is also a possible con-
tribution to the poor outcome that non-adherent patients
might have a more malignant course of the illness both
leading to non-adherence and poor outcome.
Users of depot-antipsychotics
The patients using depot-antipsychotic medication had
more relapses and more days treated by coercion both as
inpatients and outpatients and less improvement in GAF-
score during 2 years than the rest of the patients indicating
that depot-users of antipsychotics are patients with more
symptoms, lower function and less ability to cooperate
with the health services than patients with schizophrenia
that do not use depot antipsychotics. Even if 8 of 12 users
of depot-antipsychotics had relapses, only 1 of 6 adherent
Table 4: Odds for being persistent psychotic, having a relapse or being admitted to hospital for patients adherent or non adherent to 
antipsychotics or depot users.
β coefifisient (SE) Wald p Unadjusted Odds Ratio (95% CI)
Adherence with oral or depot antipsychotics
Persistent psychotic 1.29 (.68) 3.64 .056 3.63 (.967–13.64)
Relapse 2.33 (.70) 10.99 .001 10.27 (2.59–40.67)
Admitted to hospital 1.39 (.64) 4.71 .030 4.00 (1.14–13.99)
Adherence with oral antipsychotics
Persistent psychotic 1.42 (.69) 4.23 .040 4.15 (1.07–16.14)
Relapse 2.69 (.76) 12.61 .000 14.58 (3.32–64.03)
Admitted to hospital .75 (.59) 1.62 .204 2.11 (.67–6.68)
Use of depot antipsychotics
Persistent psychotic .99 (.71) 1.94 .16 2.68 (.67–10.73)
Relapse 1.96 (.72) 6.67 .010 6.44 (1.57–26.51)
Admitted to hospital .99 (.68) 2.13 .14 2.69 (.71–10.17)BMC Psychiatry 2008, 8:32 http://www.biomedcentral.com/1471-244X/8/32
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depot-users was admitted to hospital compared to 5 of 6
non-adherent users of depot antipsychotics. This indicates
that depot-users in general have a more malignant illness
than the rest of the patients, but that the depot antipsy-
chotic medication might help the patients not to be
admitted to hospital. A comparison of adherence to oral
antipsychotics with non-adherence patients combined
with depot users might be problematic. Some patients
may use depot antipsychotics on other indications than
non-adherence with oral antipsychotics. At inclusion, all
the patients in the present study were in a relative stable
clinical condition. The clinicians and raters believed that
all the patients took their medication as prescribed at
baseline, and with the exception of the 5 (10%) patients
who later revealed that they had not taken their medica-
tion at baseline, we have taken this for granted. Measure-
ment of adherence in the present study was mainly based
on patient interviews. It is a problem both for patients,
their families and physicians to accurately identify adher-
ence. Patients with substance misuse or dependency,
patients refusing to participate in the trial, patients not
discharged from their inpatient status and patients having
been ill for more than two years were excluded. Thus we
may have included a group of patients often believed to
be the most adherent to treatment of patients suffering
from schizophrenia. The present study has some limita-
tions: Patients with major substance use disorders or men-
tal retardation were excluded from the study. Substance
abuse is a robust predictor of antipsychotic non-adher-
ence and treatment discontinuation. The patients had to
be clinically stable, prescribed antipsychotic medication
and believed to be adherent to medication at baseline and
adherence to medication was not systematically evaluated
biologically. The study does not differentiate between
first-generation and second-generation antipsychotics
(excluding clozapine) and clozapine regarding the effect
on drug adherence. Problems with efficacy or tolerability
of antipsychotics may decrease a patient's volitional
adherence and affect clinical state. The small numbers of
participants, especially of those using depot-antipsychot-
ics is also a limitation of the study.
Conclusion
Non-adherence to antipsychotic medication was associ-
ated with psychotic relapses and admissions to hospital.
Users of depot antipsychotics had an increased frequency
of relapses. When users of depot antipsychotics were
adherent to medication, they had a low frequency of hos-
pital admissions. Interventions to improve adherence to
antipsychotic medication in schizophrenia is emphasised.
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